Parexel Publishes Findings on Making Clinical Research More Accessible for Gender-Diverse Populations
Parexel has published findings and recommendations for making clinical research more accessible and welcoming for transgender and nonbinary people.
While there are nearly 1.6 million transgender people in the US alone, of the thousands interventional clinical trial results published on PubMed from 2018 to 2022, Parexel notes less than one percent included participation of transgender and nonbinary patients. Many have deep-rooted reservations about healthcare and worry the risks of participating in a clinical trial would outweigh its benefits.
Through collaborating with partners and their patient advisory council and extensive research, Parexel identified five roadblocks to participation and eight solutions for designing more equitable clinical trials for transgender and nonbinary patients.
Download the study here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
